Hepatocellular Carcinoma | Disease Landscape & Forecast | G7 | 2024
The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, but the approval of immunotherapies such as atezolizumab (Roche / Genentech) plus bevacizumab, durvalumab with or without tremelimumab (AstraZeneca), nivolumab plus ipilimumab (Bristol Myers Squibb / Ono Pharmaceutical), and pembrolizumab (Merck & Co.) is causing the market to undergo a significant shift. The label expansion of immune checkpoint inhibitors into the untapped early-stage setting and the anticipated entry of novel immune checkpoint inhibitor-based combinations will expand treatment options for hepatocellular carcinoma and drive robust sales growth.
Questions answered
- How big are the clinically and commercially relevant drug-treatable hepatocellular carcinoma populations?
- What is the current treatment landscape for hepatocellular carcinoma? What are interviewed experts’ insights on current therapies?
- What are the most promising agents in the pipeline, and how will they shape the future of the hepatocellular carcinoma therapy market?
- What are the main drivers and constraints of the hepatocellular carcinoma market, and how will the market evolve over the forecast period?
Geography: United States, EU5, Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists / hepatologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and recurrent incident cases of hepatocellular carcinoma by country, segmented by drug-treatable and drug-treated early, intermediate, and advanced disease and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma therapies through 2033, segmented by brands / generics and epidemiological subpopulations.
Drug treatments: Coverage of key current and emerging therapies.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
